Natco seeks to block Gilead’s hepatitis C drug patent in India: source

(Reuters) – India’s Natco Pharma Ltd has formally asked the Indian patent office to deny U.S. drugmaker Gilead Sciences Inc’s new hepatitis C drug Sovaldi a patent in India, a source with direct knowledge of the matter said.

click to read more:

Leave a Reply

Your email address will not be published. Required fields are marked *